Stay updated on Regorafenib Pembrolizumab CRC Clinical Trial
Sign up to get notified when there's something new on the Regorafenib Pembrolizumab CRC Clinical Trial page.

Latest updates to the Regorafenib Pembrolizumab CRC Clinical Trial page
- Check4 days agoChange DetectedThe page now shows Revision: v3.3.4, replacing Revision: v3.3.3. This is a minor metadata update and does not affect study content or usability; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page introduces a new Locations section with California and Florida, replacing the former California Locations and Florida Locations entries; the revision version updated from v3.3.2 to v3.3.3.SummaryDifference0.3%

- Check54 days agoChange DetectedAdded Revision: v3.3.2 and removed Revision: v3.2.0 from the page's revision history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check61 days agoChange DetectedRemoved the government funding lapse notice from the page; this does not affect trial data, eligibility criteria, endpoints, or study results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check75 days agoChange DetectedThe two screenshots depict the same study details page with only minor layout and styling differences. No substantive content changes were observed.SummaryDifference0.4%

- Check104 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference3%

Stay in the know with updates to Regorafenib Pembrolizumab CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Regorafenib Pembrolizumab CRC Clinical Trial page.